Relmada Therapeutics, Inc. Stock OTC Markets
Stocks
RLMD
US75955J4022
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
+8.91% | +139.13% |
| Market Cap | 698M 601M 553M 519M 974M 66.33B 985M 6.55B 2.55B 32.26B 2.62B 2.56B 112B | P/E Ratio 2026 * |
-8.31x | P/E Ratio 2027 * | -6.72x |
|---|---|---|---|---|---|
| Enterprise Value | 698M 601M 553M 519M 974M 66.33B 985M 6.55B 2.55B 32.26B 2.62B 2.56B 112B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
97.1% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Relmada Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Paolo Manfredi
CTO | Chief Tech/Sci/R&D Officer | 64 | 2020-10-26 |
Sergio Traversa
CEO | Chief Executive Officer | 65 | 2012-03-31 |
Maged Shenouda
DFI | Director of Finance/CFO | 61 | 2020-01-08 |
| Director | Title | Age | Since |
|---|---|---|---|
Sergio Traversa
BRD | Director/Board Member | 65 | 2012-03-31 |
| Chairman | 80 | 2017-06-14 | |
Paul Kelly
BRD | Director/Board Member | 67 | 2015-11-11 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +8.91% | - | - | 698M | |
| +1.03% | +2.30% | +55.91% | +114.22% | 56.42B | |
| +2.72% | +3.26% | +46.05% | +44.91% | 44.54B | |
| +1.12% | +2.79% | -15.04% | -21.68% | 22.9B | |
| +1.17% | +3.85% | -0.89% | +403.86% | 21.21B | |
| +3.81% | -5.07% | +11.00% | -30.62% | 16.4B | |
| +0.15% | +2.24% | +9.32% | -39.30% | 15.4B | |
| -0.69% | +0.82% | +27.75% | +176.72% | 13.35B | |
| +5.27% | +5.54% | +19.65% | - | 12.36B | |
| +1.61% | +1.28% | +95.75% | +205.26% | 11.15B | |
| Average | +1.62% | +2.09% | +27.72% | +106.67% | 23.75B | |
| Weighted average by Cap. | +1.72% | +2.37% | +32.04% | +99.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -81.81M -70.45M -64.91M -60.84M -114M -7.78B -116M -769M -299M -3.78B -307M -300M -13.08B | -109M -93.71M -86.34M -80.93M -152M -10.35B -154M -1.02B -397M -5.03B -408M -400M -17.4B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RLMD Stock
- RLMD Stock
Select your edition
All financial news and data tailored to specific country editions
